Dual‐Nanocomplex Delivery of Neoantigen Vaccines and Doxorubicin for Synergistic Chemo‐Immunotherapy against Colorectal Cancer
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Weijian Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry & Life Science, Beijing University of Technology, NO. 100, Pingleyuan, Chaoyang, Beijing, 100124, P. R. China. Hauptthemen laut MEDLINE: Doxorubicin, Colorectal Neoplasms, Cancer Vaccines, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Colorectal cancer (CRC) is still an important global health challenge, with limited treatment efficacy. Neoantigen‐based cancer vaccines offer tumor‐specific immune activation but are limited by poor immunogenicity and rapid degradation, while chemotherapeutics like doxorubicin (DOX) suffer from non‐selective toxicity and resistance. To overcome these challenges, a dual‐nanocomplex delivery platform is developed that integrates immunotherapy and chemotherapy. The first nanocomplex, HCNPs, is functionalized with the neoantigen peptide Adpgk, CpG oligodeoxynucleotides, and hyaluronic acid (HA) via a simple self‐assembly method. The optimized HCNPs exhibited a uniform size distribution of ≈180 nm and are efficiently internalized by dendritic cells (DCs), promoting DC s maturation. The second nanocomplex, DNPs, formulated with chitosan (CS), HA, and DOX, achieved pH‐responsive release and selective tumor uptake via CD44 targeting. In vivo studies in MC‐38 tumor‐bearing mice demonstrated that combination therapy with HCNPs and DNPs significantly inhibited tumor growth, enhanced CD8⁺ IFN‐γ⁺ T cell infiltration, reduced M2 macrophage polarization, and expanded memory T cell populations. ELISPOT and LDH assays confirmed potent CTL‐mediated cytotoxicity. Importantly, no significant toxicity was observed. The results established a safe and effective nanoplatform that synergistically combines immune activation and targeted delivery, offering a promising strategy for improving CRC immunochemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry & Life Science, Beijing University of Technology, NO. 100, Pingleyuan, Chaoyang, Beijing, 100124, P. R. China.
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, P. R. China.
ORCID-Profile: Weijian Zhao, Wang Sheng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zhao, W., Noor, K. S., Sun, S., Xu, H., Meng, J., He, X., & Sheng, W. (2026). Dual‐Nanocomplex Delivery of Neoantigen Vaccines and Doxorubicin for Synergistic Chemo‐Immunotherapy against Colorectal Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503947
Vancouver
Zhao W, Noor KS, Sun S, Xu H, Meng J, He X, et al. Dual‐Nanocomplex Delivery of Neoantigen Vaccines and Doxorubicin for Synergistic Chemo‐Immunotherapy against Colorectal Cancer. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503947
BibTeX
@article{Zhao2026,
author = {Zhao, Weijian and Noor, Khattak Sameena and Sun, Siyu and Xu, Hongting and Meng, Jing and He, Xuesong and Sheng, Wang},
title = {Dual‐Nanocomplex Delivery of Neoantigen Vaccines and Doxorubicin for Synergistic Chemo‐Immunotherapy against Colorectal Cancer},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503947}
}
EUVIMED